Business Context and Reporting Period
Company: Ecology Coatings, Inc. (Note: Metadata listed "ABVC BIOPHARMA, INC." but the filing text identifies the registrant as Ecology Coatings, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Filing Date: August 19, 2009
Business Overview: The company develops nanotechnology-enabled, ultra-violet curable coatings for manufacturing efficiency in electronics, automotive, and paper product markets. The company has a limited operating history and has not yet achieved profitability.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 |
Nine Months Ended June 30, 2009 |
Nine Months Ended June 30, 2008 |
|---|---|---|---|
| Revenues | $0 | $0 | $24,884 |
| Operating Loss | $(687,699) | $(4,151,603) | $(4,296,988) |
| Net Loss | $(737,134) | $(4,373,576) | $(5,552,432) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.14) | $(0.17) |
| Cash and Cash Equivalents | $4,257 | $4,257 (Ending Balance) | $27,169 (Ending Balance) |
| Total Current Liabilities | $2,498,085 | $2,498,085 | $2,741,702 |
| Stockholders' Deficit | $(1,975,856) | $(1,975,856) | $(1,239,810) |
Debt and Liquidity: As of June 30, 2009, the company held only $4,257 in cash. Total current liabilities exceeded total assets by approximately $1.97 million. The company is in default on approximately $695,648 of short-term debt (principal and accrued interest) owed to three separate note holders.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero for the nine months ended June 30, 2009, compared to $24,884 in the prior year period. The prior year revenue was derived solely from the amortization of a 2005 licensing agreement with Red Spot.
- Net Loss: Net loss decreased by approximately $1.18 million for the nine-month period compared to the prior year. This improvement was driven by significant reductions in interest expense (down ~$1.04 million), professional fees (down ~$808,000), and salaries (down ~$414,000), partially offset by a large non-cash stock option expense of $1.37 million recognized in November 2008.
- Cash Position: Cash and cash equivalents declined from $974,276 at September 30, 2008, to $4,257 at June 30, 2009. This $970,019 decrease was primarily due to cash used in operating activities ($1.32 million) and debt repayments ($372,801), partially offset by proceeds from convertible preferred stock ($711,000).
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern. Management states that immediate additional funding is required in September 2009 to continue operations. There are no binding commitments for additional financing.
- Debt Defaults: The company is in default on notes payable to Investment Hunter, LLC, Mitchell Shaheen, and George Resta. These notes bear interest rates of 25% and were due in mid-2008. The company has made partial payments on two notes but has not paid the third.
- Related Party Transactions: The company relies heavily on financing from related parties, including Equity 11 (largest shareholder) and members of the Stromback family. Equity 11 has the right to appoint three of the five board members and the CEO.
- Internal Controls: The company disclosed a failure of its backup system in late July 2009, resulting in corrupted financial data (QuickBooks) that required manual recreation. This caused a delay in filing the 10-Q. Management has implemented manual weekly backups to CD.
- Legal Proceedings: The company filed a lawsuit against MDL Consulting Group, LLC in September 2008 alleging breach of contract and fraud. It also settled a lawsuit with Trimax, LLC in November 2008.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure the immediate funding required for September 2009 operations given the $4,257 cash balance.
- Debt Resolution: Confirm the status of negotiations regarding the $695,648 in defaulted debt and whether creditors are demanding immediate repayment or converting debt to equity.
- Revenue Generation: Assess the validity of the company's strategy to generate revenue from nanotechnology coatings, given zero revenue for the current period and a history of minimal sales.
- Dilution Risk: Review the potential dilution from outstanding options (4.28 million), warrants (4.52 million), and convertible preferred shares (potentially convertible into ~9.3 million common shares).
- Internal Control Reliability: Evaluate the risk of future financial reporting delays or errors following the recent data corruption and backup system failure.